Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3442 | SARS-CoV-2 rS/Matrix-M1 Adjuvant Wiki | 0.71 |
| drug2916 | Placebo Wiki | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
VXA-CoV2-1 is a non-replicating Ad5 vector adjuvanted oral tableted vaccine being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to evaluate the safety and immunogenicity of VXA-CoV2-1 vaccine with repeat dosing at multiple dose levels. Safety and immunogenicity will be evaluated for up to 12 months after the second dose of VXA-CoV2-1.
Description: Subject reported symptoms of local and systemic reactogenicity
Measure: Frequency of solicited symptoms of reactogenicity Time: Day 1 through Day 8 post each immunizationDescription: Subject reported symptoms of local and systemic reactogenicity
Measure: Grade of solicited symptoms of reactogenicity Time: Day 1 through Day 8 post each immunizationDescription: Any adverse events observed or reported following vaccination
Measure: Frequency of unsolicited adverse events Time: Day 1 through Day 29 post each immunizationDescription: Any adverse events observed or reported following vaccination
Measure: Grade of unsolicited adverse events Time: Day 1 through Day 29 post each immunizationDescription: Any adverse events reported following vaccination meeting definition of serious
Measure: Frequency of serious adverse events (SAEs) Time: Day 1 through Day 390Description: Any adverse events reported following vaccination meeting definition of serious
Measure: Frequency of medically-attended adverse events (MAAEs) Time: Day 1 through Day 390Description: SARS-CoV-2 specific IgG/IgA by enzyme-linked immunosorbent assay (ELISA)
Measure: SARS-CoV-2 specific IgG/IgA Time: Day 1 through Day 390Description: serum based assay of Ab titers
Measure: Neutralizing antibody titers to SARS-CoV-2 Time: Day 1 through Day 390Description: ASCs by ELISpot
Measure: Antigen-specific IgG/IgA antibody secreting (ASCs) Time: Day 1 through Day 44Description: Flow Cytometry
Measure: Th1/Th2 polarization Time: Day 1 through Day 44Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports